As the CEO of Pfizer, the world’s largest drug maker, Ian Read followed a years-long pricing strategy that reaped billions for his company. It was like clockwork: jack up prices every six months. The moves did not go entirely unnoticed, but Pfizer generally escaped much flak because other pharma companies did the same thing.

But Read’s pricing game plan didn’t seem so shrewd when President Trump entered the picture last week. Days earlier, Pfizer was virtually alone in raising prices for dozens of drugs — many by more than 9 percent — and it prompted a raging tweet from Trump. In a brief phone call with the president that Read sought on Tuesday night to defuse the uproar, the CEO backed down and deferred the hikes.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Truly good corporate governance includes practices that align the interests of the chief executive not with shareholders but with employees, customers, and society as a whole. The “shareholder value above all” mantra is responsible for much of the pathology of business today. Just saying.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy